The Clinical Effect of Rifampicin for Retreatment Cases for Pulmonary Tuberculosis |
Sung Sook Ham, Hyung Duk Kim, Won Young Lee, Ki Ho Kim |
Department of Internal Medicine, College of Medicine Yonsei University, Seoul, Korea |
재치료 폐결핵환자에 대한 Rifampicin의 임상적 효과 |
함성숙, 김형덕, 이원영, 김기호 |
|
|
Abstract |
The authors analyzed the clinical benefits and toxic effects of Rifampicin in 32 patients with prolonged previous chemotherapy wíthout effect (5cases were post-operative). The Rifampicin was given with one or more other anti-Tb. drugs for 3 to 12 months. The doses were 450-600mg once daily or biweekly.
Sputum conversion: 14 patients had positive sputum on the begining and 7 patients (50%) became nagative with Rifampicin treatment.
X-ray improvement: There was no remarkable change noticed except slight improvement in 7 cases.
Symptomatic improvement: Majority of cases showed a decrease of cough and sputm sense of wellbeing, soon after the administration of Rifampicin and also showed some gain of bodyweight.
Side effects: There was no serious side effect and serious liver function disturbance detected but one case had chill, fever and general bodyache and another case complained of general bodyache 6 to 7 months after the Rifampicin treatment. |
|